Want to see IN:CAPLIPOINT full AI Analyst Report?
Top Page
Caplin Point Laboratories Limited
(CAPLIPOINT)
Select Model
Select Model
Rating:78Outperform
Price Target:
₹2,565.00
▲(38.95% Upside)
Action:Reiterated
Date:10/01/26
The score is primarily driven by strong financial performance (steady growth, solid profitability, and an ultra-low leverage balance sheet). Technicals are supportive over the medium-to-long term but show some near-term softness. Valuation is the main constraint, with a relatively high P/E and minimal dividend yield.
Positive Factors
Consistent Revenue Growth
Consistent revenue expansion indicates durable demand for Caplin Point’s pharmaceutical portfolio and effective execution across its markets. Continued top-line growth can support operating leverage, fund product registrations, and reinforce the company’s ability to compound earnings over the next several quarters.
Negative Factors
Uneven Free Cash Flow Conversion
Although operating cash flow and free cash flow are positive, uneven conversion from reported earnings can make internally generated funding less predictable. Periodic working-capital or investment swings may limit near-term capital-allocation flexibility and require closer monitoring as the business continues to grow.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent Revenue Growth
Consistent revenue expansion indicates durable demand for Caplin Point’s pharmaceutical portfolio and effective execution across its markets. Continued top-line growth can support operating leverage, fund product registrations, and reinforce the company’s ability to compound earnings over the next several quarters.
Read all positive factors
Caplin Point Laboratories Limited (CAPLIPOINT) vs. iShares MSCI India ETF (INDA)
Market Cap
₹168.84B
Dividend Yield0.36%
Average Volume (3M)11.14K
Price to Earnings (P/E)25.4
Beta (1Y)1.35
Revenue Growth15.01%
EPS Growth17.73%
CountryIN
Employees3,406
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)84.36
Shares Outstanding76,011,696
10 Day Avg. Volume9,352
30 Day Avg. Volume11,137
Financial Highlights & Ratios
PEG Ratio0.91
Price to Book (P/B)3.19
Price to Sales (P/S)5.23
P/FCF Ratio33.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)97
Revenue Forecast (FY)₹25.01B
Caplin Point Laboratories Limited Business Overview & Revenue Model
Company Description
Caplin Point Laboratories Limited is a pharmaceutical firm actively involved in the development, manufacture, marketing, and export of both generic medications and proprietary branded products, primarily operating within India. Their extensive pro...
How the Company Makes Money
Caplin Point primarily makes money by selling pharmaceutical products (mainly generic finished-dosage formulations) in domestic and international markets, with a significant portion of revenue historically coming from exports. Its key revenue stre...
Caplin Point Laboratories Limited Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
96
Very Positive
Cash Flow
83
Very Positive
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 21.87B | 19.40B | 16.96B | 14.68B | 12.71B |
| Gross Profit | 10.50B | 11.38B | 9.40B | 7.89B | 6.99B |
| EBITDA | 8.76B | 6.53B | 5.54B | 4.43B | 3.97B |
| Net Income | 6.41B | 5.36B | 4.57B | 3.76B | 3.00B |
Balance Sheet | |||||
| Total Assets | 40.45B | 32.09B | 26.98B | 21.91B | 17.36B |
| Cash, Cash Equivalents and Short-Term Investments | 10.07B | 9.03B | 7.88B | 6.50B | 5.13B |
| Total Debt | 46.10M | 50.20M | 19.70M | 54.80M | 21.30M |
| Total Liabilities | 4.15B | 3.22B | 3.51B | 2.84B | 2.26B |
| Stockholders Equity | 35.86B | 28.50B | 23.16B | 18.80B | 14.84B |
Cash Flow | |||||
| Free Cash Flow | 3.37B | 2.41B | 1.73B | 779.00M | 2.46B |
| Operating Cash Flow | 5.85B | 4.32B | 3.18B | 2.72B | 3.37B |
| Investing Cash Flow | -6.45B | -3.35B | -3.20B | -2.18B | -3.77B |
| Financing Cash Flow | -455.90M | -383.20M | -380.70M | -281.70M | -407.10M |
Caplin Point Laboratories Limited Technical Analysis
Negative
1845.95
Price Trends
2590.94
Negative
2527.53
Negative
2143.04
Positive
Market Momentum
-115.33
Positive
29.12
Positive
7.45
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CAPLIPOINT, the sentiment is Negative. The current price of 1845.95 is below the 20-day moving average (MA) of 2541.41, below the 50-day MA of 2590.94, and below the 200-day MA of 2143.04, indicating a neutral trend. The MACD of -115.33 indicates Positive momentum. The RSI at 29.12 is Positive, neither overbought nor oversold. The STOCH value of 7.45 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:CAPLIPOINT.
Caplin Point Laboratories Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ₹168.84B | 25.38 | ― | 0.36% | 15.01% | 17.73% | |
69 Neutral | ₹111.69B | 36.43 | ― | 0.43% | 9.18% | -14.57% | |
67 Neutral | ₹258.88B | -80.67 | ― | 0.07% | 0.78% | -420.81% | |
67 Neutral | ₹94.91B | 15.40 | ― | 0.49% | 7.28% | 68.82% | |
64 Neutral | ₹199.87B | 29.85 | ― | 0.22% | 24.83% | 36.88% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₹149.20B | 41.86 | ― | 0.54% | 16.27% | -23.50% |
* General Sector Average
IN:CAPLIPOINT
Caplin Point Laboratories Limited
2,250.40
231.27
11.45%
IN:AKUMS
Akums Drugs and Pharmaceuticals Limited
679.80
218.98
47.52%
IN:GRANULES
Granules India Limited
816.80
258.61
46.33%
IN:JUBLPHARMA
Jubilant Pharmova Limited
935.75
-185.00
-16.51%
IN:PPLPHARMA
Piramal Pharma Limited
195.10
-8.55
-4.20%
IN:STAR
Strides Pharma Science Ltd
998.05
183.81
22.57%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.